Cargando…
Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
PURPOSE: Although several molecular markers predicting resistance to cetuximab- or panitumumab-based therapy of metastatic colorectal cancer were described, mutations in RAS proto-oncogenes remain the only predictors being used in daily clinical practice. However, 35%–45% of wild-type RAS patients s...
Autores principales: | Nemecek, Radim, Berkovcova, Jitka, Radova, Lenka, Kazda, Tomas, Mlcochova, Jitka, Vychytilova-Faltejskova, Petra, Slaby, Ondrej, Svoboda, Marek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968864/ https://www.ncbi.nlm.nih.gov/pubmed/27555788 http://dx.doi.org/10.2147/OTT.S102891 |
Ejemplares similares
-
MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
por: Mlcochova, Jitka, et al.
Publicado: (2015) -
Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer
por: Thorenoor, Nithyananda, et al.
Publicado: (2015) -
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients
por: Lupini, Laura, et al.
Publicado: (2015) -
Identification and functional screening of microRNAs highly deregulated in colorectal cancer
por: Faltejskova, Petra, et al.
Publicado: (2012) -
MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2019)